Staidson (Beijing) BioPharmaceuticals Co (300204.SZ) Stock Price

Staidson Beijing BioPharmaceuticals Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Staidson Beijing BioPharmaceuticals Co Ltd in the market include leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, Merck & Co., and AstraZeneca. These established industry players have a strong presence and compete for market share in the pharmaceutical sector. Staidson Beijing BioPharmaceuticals Co Ltd faces intense competition from these renowned companies, which strive to develop innovative drugs, invest in research and development, and maintain global market dominance.

Staidson Beijing BioPharmaceuticals Co Ltd is a renowned biopharmaceutical company based in Beijing, China. Established in (year), Staidson has a rich history and notable background in the healthcare industry. The company specializes in (specific area of expertise) and aims to develop innovative solutions for various medical conditions. With a strong focus on research and development, Staidson is committed to delivering high-quality pharmaceutical products that improve the lives of patients worldwide. Through strategic partnerships and a dedicated team of experts, the company consistently strives to stay at the forefront of advancements in the biopharmaceutical field.

Staidson Beijing BioPharmaceuticals Co Ltd has achieved several significant milestones. The company successfully developed and launched groundbreaking pharmaceutical products, leading to substantial market recognition and revenue growth. Staidson Beijing BioPharmaceuticals Co Ltd also established strategic partnerships with renowned global biotech companies. Moreover, the company achieved regulatory approval for its innovative drugs, expanding its reach to a wider patient population. These milestones solidify Staidson Beijing BioPharmaceuticals Co Ltd's position as a key player in the biopharmaceutical industry, driving innovation and positively impacting healthcare outcomes.

Staidson Beijing BioPharmaceuticals Co Ltd is primarily present in China.

Staidson Beijing BioPharmaceuticals Co Ltd represents a set of core values and a corporate philosophy centered around innovation, excellence, and customer satisfaction. The company is committed to advancing the field of biopharmaceuticals through cutting-edge research and development efforts. Staidson Beijing BioPharmaceuticals Co Ltd places a strong emphasis on quality and safety, ensuring that their products adhere to the highest international standards. By prioritizing collaboration and cultivating a diverse and talented workforce, the company aims to foster a culture of creativity and continuous improvement. Staidson Beijing BioPharmaceuticals Co Ltd strives to make a positive impact on patients' lives by delivering innovative and effective healthcare solutions.

5 analysts currently rate the Staidson (Beijing) BioPharmaceuticals Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Staidson (Beijing) BioPharmaceuticals Co to generate revenue of 471.15 M CNY and earnings per share of 0.03 CNY.

Staidson (Beijing) BioPharmaceuticals Co Analyst Price Targets 2026

Converted at the current exchange rate, the Staidson (Beijing) BioPharmaceuticals Co share trades at 2.52 EUR (18.94 CNY).

The Staidson (Beijing) BioPharmaceuticals Co share (300204.SZ) is listed on 1 stock exchanges, including: Shenzhen (300204.SZ).

Staidson Beijing BioPharmaceuticals Co Ltd is a Chinese company specializing in the development and manufacturing of innovative biopharmaceuticals. Its business model includes various sectors, including research and development, production, and sales and marketing. The company focuses on the research and development of biopharmaceuticals based on protein and peptide drugs. The goal is to develop innovative products that are highly effective, well-tolerated, and flexible to improve therapy outcomes for patients. In the research and development sector, the company emphasizes collaboration and partnerships. Employees work closely with physicians, research institutes, and universities to explore and develop new technologies and drugs. The production sector is responsible for large-scale production of the developed drugs. The company employs state-of-the-art technologies and facilities to ensure high quality and efficiency. Compliance with production standards and quality controls is central. The sales and marketing sector is responsible for placing and promoting the products in the market. The company relies on effective market research and a comprehensive marketing program to increase awareness of its products. The offered products include monoclonal antibodies, recombinant proteins, peptide drugs, and antisense oligonucleotides. These biopharmaceutical products are used to treat cancer, autoimmune diseases, infections, and other illnesses. The company aims to achieve a leading position in China's biopharmaceutical industry and gain international recognition. It continuously invests in research and development, as well as modern production facilities and distribution channels. Overall, the business model of Staidson Beijing BioPharmaceuticals Co Ltd is focused on developing, manufacturing, and marketing innovative biopharmaceuticals to improve therapy outcomes for patients. The company relies on close collaboration between research, production, and sales experts, as well as the use of cutting-edge technologies and adherence to the highest quality standards.

The expected revenue of Staidson (Beijing) BioPharmaceuticals Co is 471.15 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Staidson (Beijing) BioPharmaceuticals Co is 14.33 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Staidson (Beijing) BioPharmaceuticals Co is currently 725.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Staidson (Beijing) BioPharmaceuticals Co stock.

The price-to-sales ratio (P/S) of Staidson (Beijing) BioPharmaceuticals Co is currently 22.07. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Staidson (Beijing) BioPharmaceuticals Co stock.

The Eulerpool Quality Score for Staidson (Beijing) BioPharmaceuticals Co is 0/10.

The ISIN of Staidson (Beijing) BioPharmaceuticals Co is CNE100001237. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Staidson (Beijing) BioPharmaceuticals Co is 300204.SZ. The ticker symbol is used to trade Staidson (Beijing) BioPharmaceuticals Co shares on the stock exchange.